Healthy Spaces Podcast: Harnessing Heat
VIDEO: Watch Season 5 Episode 1: Harnessing Heat – Thermal Management Systems
Buildings are responsible for more than a third of global energy consumption and emissions, with much of that energy use attributed to day-to-day heating and cooling needs. The challenge to meet ambitious sustainability targets means addressing the impact of the buildings. But, could they present the biggest opportunity of all?
Thermal management systems reduce energy
In this episode, we speak to Jose La Loggia, Group President EMEA at Trane Technologies, and Stan Van Hastenberg, Sustainability Lead at Organon, a global pharmaceutical company focused on women's health.
We discuss the ins-and-outs of thermal management systems, the complexities of energy transitions and how sustainable heating and cooling innovations can contribute to a net-zero future.
Watch or listen to the full episode to hear more about how electrification solutions like electric thermal storage and heat recovery can benefit business and the environment.
Featured in this Episode:
Hosts: Dominique Silva, Marketing Leader EMEA, Trane TechnologiesScott Tew, Vice President Sustainability and Managing Director, Center for Energy Efficiency and Sustainability, Trane Technologies
Guests: Jose La Loggia, Group President, EMEA, Trane TechnologiesStan Van Hastenberg, Sustainability Lead, Organon
About Healthy Spaces
Healthy Spaces is a podcast by Trane Technologies where experts and disruptors explore how climate technology and innovation are transforming the spaces where we live, work, learn and play.
This season, hosts Dominique Silva and Scott Tew bring a fresh batch of uplifting stories, featuring inspiring people who are overcoming challenges to drive positive change across multiple industries. We'll discover how technology and AI can drive business growth, and help the planet breathe a little bit easier.
Listen and subscribe to Healthy Spaces on your favorite podcast platforms:
Apple PodcastsSpotifyYouTubeAmazon Music
How are you making an impact? What sustainable innovation do you think will change the world?
Share your story with us and learn more about the Healthy Spaces Podcast.
Visit 3BL Media to see more multimedia and stories from Trane Technologies
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a day ago
- Yahoo
Trane Technologies (TT) Expands Liquid Cooling Solutions for AI Data Centers
Trane Technologies plc (NYSE:TT) is one of the 11 best European stocks to invest in. On June 10, Trane announced the expansion of its liquid cooling capabilities for data centers. As part of the initiative, the company introduced new scalable Coolant Distribution Unit (CDU) solutions with capacities ranging from 2.5 megawatts (MW) to 10 MW. A technician in a boiler suit working on an industrial air conditioning system inside a factory. The new CDUs complement Trane's existing 1 MW CDU, providing a broader range of direct-to-chip cooling solutions. According to the company, the expanded platform is designed to address the high-density computing needs of data centers, particularly those driven by the increasing demand for artificial intelligence (AI) workloads. The company said that the new CDUs enable modular scalability. They are also optimized for high-density data centers, ensuring efficient heat transfer directly from IT equipment. Most importantly, the new platform offers up to 10 MW of cooling capacity in a space-saving, factory-skid-mounted design, which also facilitates ease of serviceability. Trane Technologies plc (NYSE:TT) is a climate solutions company based in Ireland. It designs, manufactures, and services energy-efficient heating, ventilation, air conditioning (HVAC), and refrigeration systems. Its key brands are Trane (for buildings and homes) and Thermo King (for transport refrigeration). The company operates across the Americas, EMEA, and Asia Pacific. While we acknowledge the potential of TT as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None.
Yahoo
a day ago
- Yahoo
UBS Reiterates 'Buy' on Johnson Controls (JCI) on Potential 70% Earnings Upside
Johnson Controls International plc (NYSE:JCI) is one of the 11 best European stocks to invest in. On June 17, 2025, UBS reiterated its 'Buy' rating on Johnson Controls and maintained its price target of $116.00. The investment firm cited a potential 70% earnings upside for the company from fiscal year 2025 through fiscal year 2028. UBS's analysis indicates that this growth will come on the back of structural self-help, margin catch-up, and robust capital returns. A successful financial advisor giving advice to a satisfied client in an office. UBS noted that Johnson Controls announced a $9 billion increase in its share repurchase authorization the week before June 17, 2025. Approximately $5 billion is expected to be deployed over the next three to six months. Another factor that supports UBS's positive outlook is confidence in Johnson Controls' new CEO, Joakim Weidemanis. Weidemanis took over the reins in 2024. According to UBS, the CEO has previously achieved a 600 basis point operating margin improvement at Danaher's Diagnostics business between 2020 and 2024. Johnson Controls International plc (NYSE:JCI) is a building technology and solutions company headquartered in Ireland. It designs, installs, and services smart, energy-efficient systems for heating, ventilation, air conditioning (HVAC), fire safety, security, and building management. Its leading brands include Johnson Controls and Tyco. The company operates through four segments: Building Solutions North America, EMEA/LA, Asia Pacific, and Global Products. While we acknowledge the potential of JCI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 days ago
- Business Upturn
INVESTOR DEADLINE: Robbins Geller Announces that Organon & Co. (OGN) Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit
SAN DIEGO, June 27, 2025 (GLOBE NEWSWIRE) — The law firm of Robbins Geller Rudman & Dowd LLP announces that the Organon class action lawsuit – captioned Hauser v. Organon & Co. , No. 25-cv-05322 (D.N.J.) – seeks to represent purchasers or acquirers of Organon & Co. (NYSE: OGN) securities and charges Organon as well as certain of Organon's top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Organon class action lawsuit, please provide your information here: You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Organon class action lawsuit must be filed with the court no later than Tuesday, July 22, 2025. CASE ALLEGATIONS: Organon develops and delivers health solutions through prescription therapies and medical devices. The Organon class action lawsuit alleges that defendants throughout the class period made false and/or misleading statements and/or failed to disclose that: (i) defendants concealed material information pertaining to Organon's capital allocation priorities, particularly the future of the quarterly dividend payout; (ii) in truth, Organon's optimistic reports of the dividend payout as Organon's 'number one priority' were offset by Organon's newly implemented debt reduction strategy, thus, leading to a drastic decrease – over 70% – of the quarterly dividend; and (iii) Organon planned to prioritize debt reduction following Organon's acquisition of Dermavant Sciences Ltd. The Organon class action lawsuit further alleges that on May 1, 2025, Organon reported first quarter 2025 financial results and announced that management reset Organon's dividend payout from $0.28 to $0.02. On this news, the price of Organon stock fell more than 27%, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Organon securities during the class period to seek appointment as lead plaintiff in the Organon class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Organon class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Organon class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Organon class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices. Contact: Robbins Geller Rudman & Dowd LLP J.C. Sanchez, Jennifer N. Caringal 655 W. Broadway, Suite 1900, San Diego, CA 92101 800-449-4900 [email protected]
